Molecular Underpinnings of Heart Failure, Integrative Multi-Omics, and Non-Coding RNA Profiling: the BIOCARDIUM-HF Study
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 500
- 试验地点
- 2
- 主要终点
- Heart failure hospitalization
研究概览
简要总结
The main objective of the study is to achieve a comprehensive phenotyping of patients with heart failure, combining detailed clinical characterization with in-depth molecular profiling. By integrating clinical data with cutting-edge multi-omics techniques (including transcriptomics, epigenomics, and proteomics), this research aims to identify molecular signatures, particularly non-coding RNAs (ncRNAs), that are linked to the onset and progression of HF. Through advanced molecular profiling of biological samples and the analysis of clinical parameters, including advanced imaging, hemodynamic profiling, and biomarker analysis, the study will contribute to the deep phenotyping of HF patients.
The secondary objective aims to uncover potential biomarkers that may serve as predictive indicators of disease progression and identify novel therapeutic targets, offering promising avenues for future treatments in this challenging patient population.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Female and Male, age ≥18 years at screening.
- •Diagnosis of Heart Failure according to ESC Heart Failure Guidelines
- •Ability to understand the requirements of the study and to provide informed consent.
- •Willingness to undergo follow-up.
排除标准
- •Patients will be excluded if they meet any of the following conditions:
- •Active malignancy or history of cancer with ongoing treatment (e.g., chemotherapy, radiotherapy, immunotherapy).
- •Autoimmune or systemic inflammatory diseases.
- •Concomitant infections, including acute systemic infections (e.g., sepsis, pneumonia) or chronic infections with systemic impact (e.g., HIV, hepatitis B/C with elevated transaminases).
- •Other exclusion criteria:
- •Age<18 years old
- •Inability to provide written informed consent
研究组 & 干预措施
Heart Failure with reduced ejection fraction (HFrEF)
LVEF <40%
Heart Failure with preserved ejection fraction (HFpEF)
LVEF >50%
Heart Failure with mildyly reduced ejection fraction (HFmrEF)
LVEF >40% and <50%
结局指标
主要结局
Heart failure hospitalization
时间窗: From enrollment up to five years
Death from any cause
时间窗: From enrollment up to five years
次要结局
未报告次要终点
研究者
Jan Kleeberger
Principal Investigator
University of Zurich